Related Experiment Videos
Langerhans islet preparation in cell transplantation
1Service d'Endocrinologie-Métabolisme et Diabétologie-Nutrition, Hôpital Jean Minjoz, Besançon, France.
Transfusion Science
|May 7, 1997
Summary
Islet cell transplantation offers promising symptomatic relief for Type 1 diabetes. Current limitations include the need for immunosuppression, but future strategies aim for long-term graft function without it.
Area of Science:
- Endocrinology
- Transplantation Immunology
- Regenerative Medicine
Background:
- Type 1 diabetes mellitus (T1DM) is an autoimmune disease characterized by the destruction of insulin-producing beta cells in the pancreas.
- Islet cell transplantation has emerged as a potential curative therapy for T1DM, offering near-perfect symptomatic control.
- Significant advancements in isolating and purifying human islets have led to encouraging clinical outcomes.
Purpose of the Study:
- To review the current status of islet cell transplantation in humans.
- To discuss the critical steps and challenges preceding islet transplantation.
- To explore future prospects for achieving long-term graft survival with reduced or no immunosuppression.
Main Methods:
- Review of current literature on islet cell transplantation.
- Analysis of progress in islet isolation and purification techniques.
- Evaluation of immunosuppression strategies and alternatives.
Main Results:
- Islet transplantation shows high potential for T1DM treatment with encouraging results.
- Current indications are limited by the necessity of immunosuppression, similar to whole pancreas transplantation.
- Cellular transplants offer greater flexibility for innovative strategies compared to solid organ grafts.
Conclusions:
- The ultimate goal is to achieve durable function of transplanted islets with minimal or transient immunosuppression.
- Further research into novel strategies is crucial for overcoming current limitations.
- Islet transplantation holds significant promise for the future management of Type 1 diabetes.